Search Immortality Topics:

Page 3«..2345..1020..»

Dr. John V. Prunskis, co-founder and co-Medical Director of the Illinois Pain Institute meets with Top White House Adviser – Yahoo Finance

Posted: November 11, 2019 at 9:43 am

This meeting was in follow up to the HHS Pain Task Force's final report that was submitted to Congress in May of 2019.

CHICAGO, Nov. 11, 2019 /PRNewswire-PRWeb/ --Dr. John V. Prunskis, co-founder and co-Medical Director of the Illinois Pain Institute, Presidential Appointee U.S. Department of Health and Human Services' (HHS) Pain Management Best Practices Task Force (Pain Task Force) met last Monday with Joe Grogan, the President's Assistant for Domestic Policy.

This meeting was in follow up to the HHS Pain Task Force's final report that was submitted to Congress in May of 2019.

The two discussed possible solutions to end the current opioid crisis, the advantages of Ambulatory Surgical Centers, as well as, the significant problems that plague Electronic Health Records (EHR) systems. EHR has been implicated in higher levels of physician burnout and suicide as well as contributing to the opioid crisis.

Advancements in Regenerative Medicine and current research which was supported in the Pain Task Force report was also discussed.

Dr. Prunskis, who is Hon. Consul of Lithuania, extended an invitation to President Trump and the First Lady to the upcoming Lithuanian Folk Dance Festival in Philadelphia and also invited President Trump to visit Lithuania and considered hosting a visit in Washington D.C. of Lithuanian President Nauseda.

Plans were made with other White House staff members to have follow up on these and other topics.

For more information about Dr. John V. Prunskis or the Illinois Pain Institute visit

Read more:
Dr. John V. Prunskis, co-founder and co-Medical Director of the Illinois Pain Institute meets with Top White House Adviser - Yahoo Finance

Recommendation and review posted by G. Smith

Micromotors move single cells using magnets and ultrasound – CMU The Tartan Online

Posted: November 11, 2019 at 9:43 am

A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.

These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.

Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.

Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.

The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.

We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.

The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.

Read more:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online

Recommendation and review posted by G. Smith

Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For…

Posted: November 11, 2019 at 9:43 am

DUBLIN, Nov. 11, 2019 /PRNewswire/ --Allergan plc (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (aztreonam and avibactam), for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). ATM-AVI is an investigational, fixed-dose, intravenous combination antibiotic under development globally.

"The rate of antibiotic resistance is increasing worldwide and there are limited options available to patients with these challenging and life-threatening infections, underscoring the need for the pharmaceutical industry and government to work together to bring forward new potential treatment options," said David Nicholson, EVP and Chief R&D Officer, Allergan. "The QIDP Designation shows the importance of ATM-AVI for treating serious or life-threatening infections, and the Fast Track Designation allows us to work even closer with the FDA to bring patients a new treatment faster."

The QIDP designation provides certain incentives for the development of new antibiotics, including priority review and eligibility for the FDA's Fast Track Designation, and a five-year regulatory exclusivity extension. The Fast Track Designation is designed to facilitate the development, and accelerate the review of drugs to treat serious conditions that do not have sufficient treatment options.

ATM-AVI has activity against metallo -lactamase (MBL)-producing Gram-negative pathogens, for which there are currently very limited treatmentoptions. Although aztreonam is not inactivated by metallo beta-lactamases (MBLs), as a single agent it has limited utility because the vast majority of MBL-producing pathogens also express serine--lactamases that can inactivate it. When combined with avibactam's ability to inhibit many serine--lactamases , aztreonam's activity is restored against pathogens that co-produce MBLs and serine enzymes, thus presenting a new treatment for patients with these infections. ATM-AVI is currently in Phase III trials.

ATM-AVI is being jointly developed with Pfizer. Allergan holds the rights to commercialize ATM-AVI in North America, while Pfizer holds the rights to commercialize this investigational therapy in the rest of the world.

ATM-AVI is a drug candidate under development and supported by public-private partnerships between Pfizer and the Biomedical Advanced Research and Development Authority (BARDA)*, and between Pfizer and the European Union's Innovative Medicines Initiative (IMI) a partnership between the European Union and the European pharmaceutical industry, under a project called COMBACTE-CARE(Combating Bacterial Resistance in Europe Carbapenem Resistance)**. Allergan's anti-infective portfolio also includes AVYCAZ(ceftazidime and avibactam), TEFLARO(ceftaroline fosamil), DALVANCE(dalbavancin) and MONUROL(fosfomycin tromethamine).

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences;difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

*This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under OTA number HHSO100201500029C.

**This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no 115620 resources of which are composed of financial contribution form the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.




Manisha Narasimhan, PhD

(862) 261-7488


Lisa Brown

(862) 261-7320

SOURCE Allergan plc

Original post:
Allergan Receives FDA Qualified Infectious Disease Product (QIDP) Designation And Fast Track Designation For ATM-AVI (Aztreonam And Avibactam) For...

Recommendation and review posted by G. Smith

Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology – WRAL Tech Wire

Posted: November 11, 2019 at 9:43 am

WILMINGTON Cucalorus Connect, held Nov. 14 and 15 in Wilmington, explores the intersection between creativity, technology, and humanity, this year with a different structure and emphasis on innovative healthcare technology.

The two-day gathering brings people together to discuss what kind of future we could build if we use innovation and technology to expand our sense of humanity. The conference features leading thinkers on health, finance, startups, coastal resilience, racial justice.

This year says Dan Brawley, director of Cucalorus, the structure of the event has changed. Its more holistic and less compartmentalized. As it evolved, weve gotten more clear about the type of experience we wanted to create for people.

Dan Brawley, director of Cucalorus. Photo by R Wright.

Though it began as primarily a business conference, It isnt just a conference about how to make money, Brawley said. Its a conference about how to make the world a better place using technology and creativity.

Nick Adkins, co-founder of Pinksocks Life, a nonprofit organization focused on promoting human connection around the world, will deliver the keynote address on The Power of Connection

The pinksocks movement empowers people from all walks of life to connect with anyone, anywhere, by creating a global tribe of pinksocks-wearing people who are focused on empathy, caring and love. The movement has been decommoditized from its beginning in 2015 all pinksocks are gifts. Every connection made between the gift giver and recipient is based on an authentic connection, not a transaction.

Pinksocks movement founder Nick Adkins keynotes Cucalorus Connect this year. Photo courtesy of Cucalorus.

There is a lot of focus in the program on the future of healthcare with an emphasis on helping people discover new ways to use innovation and technology. How mind-bending it is that you can improve your health in ways we never imagined, said Brawley.

One of the sessions Brawley finds most interesting is Marie Johnsons Digital Humans in Healthcare. Johnson will talk about what she sees as her moon shot, where digital humans are part of an augmented health ecosystem: helping patients and reducing staff burnout.

The digital avatars talk to you all the time and have to be real and authentic, notes Brawley. Its challenging, he said, Ten times harder than making a movie.

Johnson, an Australian entrepreneur, conceived and led the global co-design effort with people with disabilities to deliver Nadia the first AI digital human for service delivery. This work sparked a global industry and appetite for AI-powered digital humans.

An AI Digital Human Cardiac Coach is Johnsons current effort. Its day to day indicators may even be able to predict when a patient will suffer a heart attack. Its a wildly creative app that promises to change things, Brawley said. Some of the most creative people in the world are computer programmers. The things they do with ones and zeroes are incredible.

Film explores regenerative medicine

Other health-focused sessions include Regenerative Medicine in the film Five Minutes. Five Minutes is a film about Baptiste Touissants recovery when a suicide bomber detonated only feet from him in Afghanistan and his hope for regenerative medicine (RM) for U.S. soldiers.

RM promises a future where doctors, using a soldiers own cells, rebuild genitalia and reconstruct arms and legs blown apart by shrapnel. The animated narrative film is a five-year effort directed, produced and edited by Wake Forest University faculty. Wake Forest is a leader in RM research.

More Than Words: how visuals can help us heal healthcare, examines how words alone cant efficiently explain bodily sensations or lifetime journeys. They cant sufficiently show emotions or trauma. As a result, patients and doctors often dont understand each other, and our broken healthcare system bumbles along. This session will feature stories from a doctor and a patient who have each discovered new ways of communicating using visuals and drawing.

Apart from the healthcare focus, one of the most interesting sessions is Youre in the matrix and just dont know it. Two University of North Carolina at Wilmington professors discuss the possibility that we may all be living in the paradigm developed in The Matrix movie franchise.

Dr. Curry Guinn and Dr. Julian Keith, UNCW professors, will discuss the possibility that were in the matrix and dont know it. Photo by R Wright.

The conference does still cover hot business topics, from the Influence of Design, to Martech. Martech is the latest buzzword in the marketing industry. It refers to any technology that a marketer can use to reach a potential customerfrom social media scheduling platforms to email.

Thesession highlights how to use Martech in all phases of marketing and PR campaigns from strategic planning to implementation and results measurement with the goal to create efficient and effective campaigns.

Another session looks at Blockchain technology, contrasting whats hot vs. whats hype.

Image courtesy of Cucalorus

The 10X10 Challenge returns this year. Ten entrepreneurs are paired with 10 filmmakers and challenged to make a three-minute promo video in five days. The films are shown on Sunday. The Rocket Pitch event is a fast-paced pitch competition. startups go head-to-head with just 90 seconds and one slide to capture audience votes.


Brandon Noel

An all-in-one solution compliance platform for North Carolina bars to manage members.

GreenStream Technologies

Karen Lindquist

Monitors and reports conditions in the environment with an end-to-end solution for floods in urban, suburban, rural and even remote environments.

Language Corpus

Reid Wilson

A subscription-based offering for intermediate and advanced language learners to understand what people are saying to them, around them and about them.


David Stone

Apartment complexes share what is known as a competitive portfolio. Survei speeds up the process, while also increasing data reliability.

Safe and Sound

Elizabeth Baker, Stacey Kolomer

A disaster management mobile app which informs managers of colleagues locations in a crisis, while maintaining security and privacy for a healthy work/life balance not given when using social media.


Claire Holroyd

A toolkit proven in the real world with thousands of teachers and children to make the most of childs early development and learning through play.

See the 10X20 and Rocket pitch session description for links to the companies.

Cucalorus Connect Conference Nov. 14-15 explores intersection of creativity and technology - WRAL Tech Wire

Recommendation and review posted by G. Smith

Would you like to know about Cell Expansion Market 2025 Research Report? Key players- GE Healthcare Life Sciences, Thermo Fisher Scientific,…

Posted: November 11, 2019 at 9:43 am

Know the Future Opportunities Cell Expansion Market 2019

New research report, titled Cell Expansion Market Analysis, Research, Share, Growth, Sales, Trends, Supply, and Forecast to 2025. The present report gauges the Cell Expansion market across the world and also analyzes the essential macro and micro-economic factors affecting the progress of the market.

Get a Sample PDF Report:

manufacturers included in the study are: , GE Healthcare Life Sciences, Thermo Fisher Scientific, Terumobct, Xpand Biotechnology, BINKIT, AMMSTM, Lonza Group, Terumo, Becton Dickinson

The main points which are answered and covered in this Report are-

What will be the total Cell Expansion Market in the coming years till 2025?What will be the key factors which will be overall affecting the industry?What are the various challenges addressed?Which are the major companies included?

The Important Type Coverage in the Market areReagentMediaBioreactor

Market Segment by Applications, coversRegenerative MedicineCell BankingCancer ResearchOther

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Get Discount on this Report:

The fundamental purpose of Cell Expansion Market report is to provide a correct and strategic analysis of the Cell Expansion industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Cell Expansion market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Additionally, the report quotes worldwide certainties and countenance of Cell Expansion industry along with a downstream and upstream analysis of leading players. Numerous research findings and conclusions stated in the report will help decision makers to take imperative decisions in the near future.

The Cell Expansion Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Table of Content:Cell Expansion Research Report 2019-2025Chapter 1: Cell Expansion OverviewChapter 2: Cell Expansion Economic ImpactChapter 3: Competition by ManufacturerChapter 4: Production, Revenue (Value) by Region (2019-2025)Chapter 5: Supply (Production), Consumption, Export, Import by Regions (2019-2025)Chapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market Forecast (2019-2025)Chapter 15: Appendix

Thank You For Visiting Our Report .

View Full Report@

Would you like to know about Cell Expansion Market 2025 Research Report? Key players- GE Healthcare Life Sciences, Thermo Fisher Scientific,...

Recommendation and review posted by G. Smith

A bioengineering researcher who studies how vaping affects lung function sees a future with more blind scientists – News@Northeastern

Posted: November 11, 2019 at 9:42 am

Mona Minkarastood on a train platform in Johannesburg, South Africa, tapping at her phone in frustration. The GPS was malfunctioning and the devices automated voice kept repeating that there was no transit information available.

Minkara, a newly appointed assistant professor of bioengineering at Northeastern, has been blind since she was seven years old. She was in Johannesburg filming the first part of a documentary series demonstrating how she navigates public transportation around the world.

I always tell people I cant wait to get lost, Minkara says. Sometimes society tells you, Youre blind, so you cant do this. So my freedom matters so much to me.

In July, Minkara was awarded the Holman Prize by LightHouse for the Blind and Visually Impaired, which is given to individuals who are blind and want to push their limits with some sort of groundbreaking adventure. The award is named for James Holman, a blind, Victorian-era explorer who spent years traveling the world alone and successfully circumnavigated the globe.

As with Holman, Minkaras adventure is rooted in solo exploration. She started with a trip to Johannesburg in October. In December, she will fly to London, and explore Istanbul, Singapore, and Tokyo before returning home. She is traveling with a videographer, but the woman is not allowed to help her in any way other than by filming what happens.

The footage will be made into a five-episode documentary series called Planes, Trains, and Canes, which will be released on YouTube in 2020. Minkara intends the series to show how blind people deal with different public transportation systems, and that adventure is possible for anyone.

It gives me a sense of freedom, to be in a city that has good public transportation, Minkara says. It means I can do my own thing for myself. Thats huge.

At Northeastern, Minkara is using her background in computational chemistry to study molecules that reside on the inner surface of our lungs, called pulmonary surfactants. They reduce the surface tension of water, which allows our lungs to expand more easily, helping us breathe.

Minkara will be modeling this substance at the molecular level. Her work could help researchers understand how vaping affects our lung function, as well as lead to better treatments for diseases such as respiratory distress syndrome.

To do her research, Minkara works with access assistants who take notes, proof-read publications, and trace the shape of plots on the back of Minkaras hand, so she can understand what they look like. Their assistance is invaluable, Minkara says, but she hopes blind researchers will have more tools in the future, such as tactile plots or braille displays, that could provide tangible access to the different images they are working with.

Minkara, who grew up watching The Magic School Bus and reading stories of Sherlock Holmes, knew she wanted to be a scientist. Her blindness didnt change that goal.

I actually started out undergrad wanting to be a surgeon, she says with a laugh. I remember having a conversation with the pre-med advisor saying something like, Would you want a blind person cutting up your brain? And I thought, Hmm, maybe were not ready yet, as a society.

Instead, Minkara pursued computational chemistry. When she took a postdoctoral position at the University of Minnesota, her advisor, J. Ilja Siepmann, helped Minkara realize that her blindness was actually a strength in scientific research.

Siepmann pointed out that being blind had taught Minkara to think differently and solve problems in creative ways. He wanted her in his lab because those skills would help her approach research questions from different angles, and see things that a sighted person might miss.

It just floored me, Minkara says. It was the first time in my professional life in which somebody saw my blindness as an asset, when I had felt like I needed to keep on running to keep up with my peers.

And she envisions a future with a lot more blind researchers.

There are a lot of hurdles, but I personally feel like theyre worth overcoming, Minkara says. I want to be there for kids that are trying to be scientists and are blind. Or really, any kid that is trying to do something that society thinks they cant.

For media inquiries, please contact

See more here:
A bioengineering researcher who studies how vaping affects lung function sees a future with more blind scientists - News@Northeastern

Recommendation and review posted by G. Smith

Page 3«..2345..1020..»